Polygenic Risk Scores Validated in Patient‐Derived Cells Stratify for Mitochondrial Subtypes of Parkinson's Disease
Annals of Neurology · 2024-07 · 96 (1) · 133-149
DOI: 10.1002/ana.26949 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Neurology, online erschienen am 20.05.2024. Verfasst von Giuseppe Arena und 22 weiteren Autor:innen. Beteiligte Einrichtung: Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg. Hauptthemen laut MEDLINE: Parkinson Disease, Multifactorial Inheritance, Mitochondria. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Fonds National de la Recherche Luxembourg.
Abstract (Originalsprache)
Objective
The aim of our study is to better understand the genetic architecture and pathological mechanisms underlying neurodegeneration in idiopathic Parkinson's disease (iPD). We hypothesized that a fraction of iPD patients may harbor a combination of common variants in nuclear‐encoded mitochondrial genes ultimately resulting in neurodegeneration.
Methods
We used mitochondria‐specific polygenic risk scores (mitoPRSs) and created pathway‐specific mitoPRSs using genotype data from different iPD case–control datasets worldwide, including the Luxembourg Parkinson's Study (412 iPD patients and 576 healthy controls) and COURAGE‐PD cohorts (7,270 iPD cases and 6,819 healthy controls). Cellular models from individuals stratified according to the most significant mitoPRS were subsequently used to characterize different aspects of mitochondrial function.
Results
Common variants in genes regulating Oxidative Phosphorylation (OXPHOS ‐PRS ) were significantly associated with a higher PD risk in independent cohorts (Luxembourg Parkinson's Study odds ratio, OR = 1.31[1.14–1.50], p ‐value = 5.4e‐04; COURAGE‐PD OR = 1.23[1.18–1.27], p ‐value = 1.5e‐29). Functional analyses in fibroblasts and induced pluripotent stem cells‐derived neuronal progenitors revealed significant differences in mitochondrial respiration between iPD patients with high or low OXPHOS ‐PRS ( p ‐values < 0.05). Clinically, iPD patients with high OXPHOS ‐PRS have a significantly earlier age at disease onset compared to low‐risk patients (false discovery rate [FDR]‐adj p ‐value = 0.015), similar to prototypic monogenic forms of PD. Finally, iPD patients with high OXPHOS ‐PRS responded more effectively to treatment with mitochondrially active ursodeoxycholic acid.
Interpretation
OXPHOS ‐PRS may provide a precision medicine tool to stratify iPD patients into a pathogenic subgroup genetically defined by specific mitochondrial impairment, making these individuals eligible for future intelligent clinical trial designs. ANN NEUROL 2024;96:133–149
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Luxembourg Centre for Systems Biomedicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
- Translational Neurodegeneration Section "Albrecht-Kossel", Department of Neurology, University Medical Center Rostock, University of Rostock, Rostock, Germany.
- Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.
- Centre for Genetic Epidemiology, Institute for Clinical Epidemiology and Applied Biometry, University of Tübingen, Tübingen, Germany.
- Transversal Translational Medicine, Luxembourg Institute of Health, Strassen, Luxembourg.
- Parkinson Research Clinic, Centre Hospitalier du Luxembourg, Luxembourg, Luxembourg.
ORCID-Profile: Giuseppe Arena, Paul Antony, Dheeraj Reddy Bobbili, Christine Klein, Oliver Bandmann, Manu Sharma, Rejko Krüger, Patrick May, Anne Grünewald
Förderung
- Deutsche Forschungsgemeinschaft
- Fonds National de la Recherche Luxembourg
Zitieren
APA
Arena, G., Landoulsi, Z., Grossmann, D., Payne, T., Vitali, A., Delcambre, S., Baron, A., Antony, P., Boussaad, I., Bobbili, D. R., Sreelatha, A. A. K., Pavelka, L., J Diederich, N., Klein, C., Seibler, P., Glaab, E., Foltynie, T., Bandmann, O., Sharma, M., …, & NCER‐PD and COURAGE‐PD Consortia (2024). Polygenic Risk Scores Validated in Patient‐Derived Cells Stratify for Mitochondrial Subtypes of Parkinson's Disease. Annals of Neurology, 96(1), 133-149. https://doi.org/10.1002/ana.26949
Vancouver
Arena G, Landoulsi Z, Grossmann D, Payne T, Vitali A, Delcambre S, et al. Polygenic Risk Scores Validated in Patient‐Derived Cells Stratify for Mitochondrial Subtypes of Parkinson's Disease. Annals of Neurology. 2024;96(1):133-149. doi:10.1002/ana.26949
BibTeX
@article{Arena2024,
author = {Arena, Giuseppe and Landoulsi, Zied and Grossmann, Dajana and Payne, Thomas and Vitali, Armelle and Delcambre, Sylvie and Baron, Alexandre and Antony, Paul and Boussaad, Ibrahim and Bobbili, Dheeraj Reddy and Sreelatha, Ashwin Ashok Kumar and Pavelka, Lukas and J Diederich, Nico and Klein, Christine and Seibler, Philip and Glaab, Enrico and Foltynie, Thomas and Bandmann, Oliver and Sharma, Manu and Krüger, Rejko and May, Patrick and Grünewald, Anne and NCER‐PD and COURAGE‐PD Consortia, NCER‐PD and COURAGE‐PD Consortia},
title = {Polygenic Risk Scores Validated in Patient‐Derived Cells Stratify for Mitochondrial Subtypes of Parkinson's Disease},
journal = {Annals of Neurology},
year = {2024},
volume = {96},
number = {1},
pages = {133--149},
doi = {10.1002/ana.26949}
}
EUVIMED